Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Cancer Center Division
77 active people
85 grants
Recent Grants
A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer
2024
·
$502.8K
cancer,
metastasis,
drug combination,
treatment,
clinical trial
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for
2024
·
$345.7K
breast cancer,
adjuvant therapy,
immunotherapy,
clinical trial,
hormone receptor
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
2023
·
$2.1M
clinical trials,
oncology,
pharmacokinetics,
safety,
efficacy
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors
2023
·
$830.5K
oncology,
clinical trials,
cancer treatment,
drug development,
immunotherapy
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
2023
·
$825.5K
oncology,
clinical trials,
immunotherapy,
cancer treatment,
drug efficacy
A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)
2023
·
$770.6K
cell therapy,
diabetes,
chronic kidney disease,
clinical trial,
renal therapy
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors and Subsequent Expansio
2023
·
$735.4K
cancer,
pharmacokinetics,
clinical effects,
intravenous administration,
safety
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have R
2023
·
$709.8K
breast cancer,
immunotherapy,
clinical trials,
combination therapy,
precision medicine
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
2023
·
$684.8K
cancer treatment,
drug trial,
dose escalation,
solid tumors,
lymphomas
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
2023
·
$568.2K
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
2023
·
$560.9K
ovarian cancer,
combination therapy,
platinum-resistant,
peritoneal cancer,
fallopian-tube cancer
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tai-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom
2023
·
$546.3K
clinical trials,
immunotherapy,
multiple myeloma,
combination therapy,
drug development
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers
2023
·
$509.8K
cancer,
chemotherapy,
clinical trial,
treatment,
combination therapy
Ultra-Performance Liquid Chromatography - Triple Quadrupole Mass Spectrometry System
2023
·
$504.4K
chromatography,
mass spectrometry,
analytical chemistry,
instrumentation,
chemical analysis
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
2023
·
$494.2K
cancer,
immunotherapy,
clinical trials,
metastasis,
treatment comparison
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
2023
·
$464.7K
cell therapy,
cancer treatment,
crispr,
lymphoma,
clinical trial
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Canc
2023
·
$454.6K
prostate cancer,
cancer treatment,
clinical trial,
metastatic cancer,
drug combination
Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies
2023
·
$432.5K
gsk-3b inhibitor,
hematologic malignancies,
chemotherapy
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate
2023
·
$419.4K
chemotherapy,
antibody-drug conjugate,
ovarian cancer,
clinical trial,
folate receptor
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors
2023
·
$391.4K
immunotherapy,
cancer,
clinical trial,
combination therapy,
solid tumors
People
Ann Bridges
Conference and Events Planner II
AJ Steuer
Research Compliance Administrator I
Aradhana Kari
Research Compliance Administrator II
Alaina Krone
Clinical Research Manager III
Amy Carrier
Research Nurse III
Angelica Erunez
Research Compliance Administrator II
Angelique Thornton
Research Nurse II
Antonio Poleon Philippe
Community Outreach Professional I
Amy Selegue
Clinical Research Manager II
Angela Yung
Researcher/Scientist III
Bryan Clines
Research Compliance Administrator III
Beth Estevez Quintana
Clinical Research Coordinator II
Betsey Wagener
Research Program Administration Manager IV
Betsy Wertheim
Biostatistician II
Brianna Loughran
Clinical Research Coordinator II
Brianna Denton
Research Compliance Manager I
Bethany Skovan
Research Specialist, Senior
Carolina Pineda
Administrative Support Assistant III
Catherine Cordova
Research Professional I
Michele Chu-Pilli
Research Program Administration Officer III
Carolyn Lane
Research Laboratory Manager I
Carole Kepler
Laboratory Coordinator II
Carol Carpenter
Research Development Professional IV
Daniel Buster
Researcher/Scientist IV
Dakota Hartliep
Research Technician II
Diana Dawson
Research Compliance Administrator II
Francois Chu
Research Compliance Administrator I
Lupita Ramos-Barrera
Clinical Research Manager I
Gillian Paine-Murrieta
Research Laboratory Manager III
Haiyan Cui
Research Specialist, Senior
Hubert Bartels
Systems Administrator II
Jaime Gard
Laboratory Coordinator III
Jose Guillen-R
Biostatistician II
Kai Kau
Clinical Research Coordinator I
Kathleen Molinar
Research Program Administration Officer II
Kathylynn Saboda
Biostatistician II
Carmen Arredondo
Administrative Support Assistant I
Laura Duckett
Clinical Research Coordinator III
Lora Inclan
Clinical Research Coordinator III
Lizeth Evangelista
Research Compliance Administrator II
Elizabeth McPeak
Clinical Research Manager IV
Linda Maynard
Research Program Administration Officer I
Liliana Mendivil
Community Outreach Professional I
Maga Sanchez
Research Laboratory Manager I
Namoonga Mantina
Community Outreach Manager I
Marco Padilla-Rodriguez
Researcher/Scientist IV
Mark Febbo
Communications Manager III
Michelle Perez-coronado
Community Outreach Professional I
Mitzi Miranda
Research Program Administration Officer III
Michael Yozwiak
Researcher/Scientist III
Mary Krutzsch
Research Specialist, Senior
Melissa Molina
Research Compliance Administrator II
Maria Prevatt
Research Program Administration Officer IV
Monica Yellowhair
Community Outreach Manager II
Michele Holland
Research Compliance Administrator II
Niyuri Fleming
Clinical Research Manager I
Octavio Castanos
Research Compliance Administrator II
Camilo Ortiz
Community Outreach Professional I
Prisca Zimmerman
Project Manager III
Patricia Robles Quihuis
Research Nurse III
Ruth Canamar
Research Program Administration Officer III
Rebecca Crocker
Research Program Administration Officer II
Rosa Fung
Financial Analysis Manager IV
Debora Aguirre
Administrative Support Assistant III
H-H. Sherry Chow
Research Scientist
Sylvia DeCero
Research Nurse III
Sophia Farrisi
Laboratory Coordinator I
Sarah Travis
Clinical Research Coordinator II
Sandra Ortega
Clinical Research Coordinator II
Jaron Solsky
Clinical Research Manager I
Stephanie Soto
Clinical Research Coordinator III
Sylvia Paton
Clinical Research Manager III
Sonja Velickovic
Laboratory Coordinator I
Tiffanie Cagle
Clinical Research Coordinator II
Teri Bankhead
Administrative Operations Manager V
Terri Katz
Research Compliance Administrator I
Wade Chew
Research Technologist III
Research expenses history
Funding support
7 funding agencies since 2020